Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 111

1.

Utilizing toxicogenomic data to understand chemical mechanism of action in risk assessment.

Wilson VS, Keshava N, Hester S, Segal D, Chiu W, Thompson CM, Euling SY.

Toxicol Appl Pharmacol. 2013 Sep 15;271(3):299-308. doi: 10.1016/j.taap.2011.01.017. Epub 2011 Feb 2. Review.

PMID:
21295051
2.

Application of toxicogenomics in hepatic systems toxicology for risk assessment: acetaminophen as a case study.

Kienhuis AS, Bessems JG, Pennings JL, Driessen M, Luijten M, van Delft JH, Peijnenburg AA, van der Ven LT.

Toxicol Appl Pharmacol. 2011 Jan 15;250(2):96-107. doi: 10.1016/j.taap.2010.10.013. Epub 2010 Oct 21. Review.

PMID:
20970440
3.

Systems toxicology: applications of toxicogenomics, transcriptomics, proteomics and metabolomics in toxicology.

Heijne WH, Kienhuis AS, van Ommen B, Stierum RH, Groten JP.

Expert Rev Proteomics. 2005 Oct;2(5):767-80. Review.

PMID:
16209655
4.

An approach for integrating toxicogenomic data in risk assessment: the dibutyl phthalate case study.

Euling SY, Thompson CM, Chiu WA, Benson R.

Toxicol Appl Pharmacol. 2013 Sep 15;271(3):324-35. doi: 10.1016/j.taap.2013.03.013. Epub 2013 Mar 26.

PMID:
23537663
5.

Use of genomic data in risk assessment case study: I. Evaluation of the dibutyl phthalate male reproductive development toxicity data set.

Makris SL, Euling SY, Gray LE Jr, Benson R, Foster P.

Toxicol Appl Pharmacol. 2013 Sep 15;271(3):336-48. doi: 10.1016/j.taap.2010.09.006. Epub 2010 Sep 16.

PMID:
20849870
6.

Toxicogenomics for the prediction of toxicity related to herbs from traditional Chinese medicine.

Youns M, Hoheisel JD, Efferth T.

Planta Med. 2010 Dec;76(17):2019-25. doi: 10.1055/s-0030-1250432. Epub 2010 Oct 18. Review.

PMID:
20957595
7.

Current and future use of genomics data in toxicology: opportunities and challenges for regulatory applications.

Goetz AK, Singh BP, Battalora M, Breier JM, Bailey JP, Chukwudebe AC, Janus ER.

Regul Toxicol Pharmacol. 2011 Nov;61(2):141-53. doi: 10.1016/j.yrtph.2011.07.012. Epub 2011 Aug 5.

PMID:
21840362
8.

Toxicogenomic approach for assessing toxicant-related disease.

Waters MD, Olden K, Tennant RW.

Mutat Res. 2003 Nov;544(2-3):415-24. Review.

PMID:
14644344
9.

Use of genomic data in risk assessment case study: II. Evaluation of the dibutyl phthalate toxicogenomic data set.

Euling SY, White LD, Kim AS, Sen B, Wilson VS, Keshava C, Keshava N, Hester S, Ovacik MA, Ierapetritou MG, Androulakis IP, Gaido KW.

Toxicol Appl Pharmacol. 2013 Sep 15;271(3):349-62. doi: 10.1016/j.taap.2011.06.014. Epub 2011 Jun 30.

PMID:
21745491
10.

Toxicogenomics: regulatory perspective on current position.

Battershill JM.

Hum Exp Toxicol. 2005 Jan;24(1):35-40. Review.

PMID:
15727054
11.

Integrating mechanistic and polymorphism data to characterize human genetic susceptibility for environmental chemical risk assessment in the 21st century.

Mortensen HM, Euling SY.

Toxicol Appl Pharmacol. 2013 Sep 15;271(3):395-404. doi: 10.1016/j.taap.2011.01.015. Epub 2011 Feb 1.

PMID:
21291902
12.

Clearing the standards landscape: the semantics of terminology and their impact on toxicogenomics.

Burgoon LD.

Toxicol Sci. 2007 Oct;99(2):403-12. Epub 2007 May 5.

PMID:
17483496
13.

Pathway analysis tools and toxicogenomics reference databases for risk assessment.

Ganter B, Zidek N, Hewitt PR, Müller D, Vladimirova A.

Pharmacogenomics. 2008 Jan;9(1):35-54. Review.

PMID:
18154447
14.

Contribution of new technologies to characterization and prediction of adverse effects.

Rouquié D, Heneweer M, Botham J, Ketelslegers H, Markell L, Pfister T, Steiling W, Strauss V, Hennes C.

Crit Rev Toxicol. 2015 Feb;45(2):172-83. doi: 10.3109/10408444.2014.986054. Epub 2015 Jan 23. Review.

PMID:
25615431
15.

Gene expression profiling to identify potentially relevant disease outcomes and support human health risk assessment for carbon black nanoparticle exposure.

Bourdon JA, Williams A, Kuo B, Moffat I, White PA, Halappanavar S, Vogel U, Wallin H, Yauk CL.

Toxicology. 2013 Jan 7;303:83-93. doi: 10.1016/j.tox.2012.10.014. Epub 2012 Nov 9.

16.

The use of toxicogenomic data in risk assessment: a regulatory perspective.

Chan VS, Theilade MD.

Clin Toxicol (Phila). 2005;43(2):121-6. Review.

PMID:
15822767
17.

Inter- and intra-laboratory study to determine the reproducibility of toxicogenomics datasets.

Scott DJ, Devonshire AS, Adeleye YA, Schutte ME, Rodrigues MR, Wilkes TM, Sacco MG, Gribaldo L, Fabbri M, Coecke S, Whelan M, Skinner N, Bennett A, White A, Foy CA.

Toxicology. 2011 Nov 28;290(1):50-8. doi: 10.1016/j.tox.2011.08.015. Epub 2011 Aug 19.

PMID:
21871943
18.

Current and future applications of toxicogenomics: Results summary of a survey from the HESI Genomics State of Science Subcommittee.

Pettit S, des Etages SA, Mylecraine L, Snyder R, Fostel J, Dunn RT 2nd, Haymes K, Duval M, Stevens J, Afshari C, Vickers A.

Environ Health Perspect. 2010 Jul;118(7):992-7. doi: 10.1289/ehp.0901501. Epub 2010 Jan 25.

19.

How can toxicogenomics inform risk assessment?

Oberemm A, Onyon L, Gundert-Remy U.

Toxicol Appl Pharmacol. 2005 Sep 1;207(2 Suppl):592-8. Review.

PMID:
15990130
20.

Integrating toxicogenomics into human health risk assessment: lessons learned from the benzo[a]pyrene case study.

Chepelev NL, Moffat ID, Labib S, Bourdon-Lacombe J, Kuo B, Buick JK, Lemieux F, Malik AI, Halappanavar S, Williams A, Yauk CL.

Crit Rev Toxicol. 2015 Jan;45(1):44-52. doi: 10.3109/10408444.2014.973935. Review.

PMID:
25605027

Supplemental Content

Support Center